JPRN-UMIN000004616已完成2 期
A randomized phase ll study comparing neoadjuvant FAP and DCF for the resectable advanced esophageal cancer (OGSG 1003) - A randomized phase ll study comparing neoadjuvant FAP and DCF for the resectable advanced esophageal cancer (OGSG 1003)
OGSG0 个研究点目标入组 162 人开始时间: 2010年12月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 162
研究概览
简要总结
The R0 resection rates for the ACF and DCF groups were equivalent (95.9% versus 96.2%, P=0.93). The 2-year RFS and overall survival rates for DCF versus ACF were 64.1% versus 42.9% (hazard ratio 0.53, 95% confidence interval 0.33-0.83, P=0.0057) and 78.6% versus 65.4% (P=0.08), respectively.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.Unresectable due to severe organ dysfunction (brain, heart, lung, liver, and/or kidney) 2.With active double cancers 3.With the history of severe drug allergy 4.Pregnant and/or nursing women, or women who expect to be pregnant 5.Patients whom doctor in chief decides not to register to this study
研究者
相似试验
招募中
2 期
A study comparing preoperative chemotherapy with preoperative chemoradiotherapy for advanced esophageal (foodpipe) cancerCTRI/2013/03/003497Tata MemorialHospital100
Unknown
2 期
Study of Nimotuzumab in Combination With Neoadjuvant Chemotherapy for Resectable Esophageal Squamous Cell CarcinomaEsophageal Squamous Cell Carcinoma ResectableNCT01688700Zhejiang Cancer Hospital60
招募中
2 期
Randomized phase II trial of DCF-R vs CF-R in unresectable and recurrent esophageal cancerJPRN-UMIN000018443Gunma University Hospital Integrative center of general surgery52
进行中（未招募）
1 期
A Randomized Phase-2 Trial to Evaluate the Effects of the IRX-2 Regimen before Surgery and after Chemotherapy or Radiation in Newly Diagnosed Patients with Stage II, III or IVA Squamous Cell Cancer of the Oral Cavityewly Diagnosed Stage II, III or IVA Squamous Cell Carcinoma of the Oral Cavity.MedDRA version: 19.0Level: PTClassification code 10041857Term: Squamous cell carcinoma of the oral cavitySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-000373-21-ESIRX Therapeutics, Inc.200
进行中（未招募）
1 期
A Randomized Phase-2 Trial to Evaluate the Effects of the IRX-2 Regimen before Surgery and after Chemotherapy or Radiation in Newly Diagnosed Patients with Stage II, III or IVA Squamous Cell Cancer of the Oral Cavityewly Diagnosed Stage II, III or IVA Squamous Cell Carcinoma of the Oral Cavity.MedDRA version: 20.0Level: PTClassification code 10041857Term: Squamous cell carcinoma of the oral cavitySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-000373-21-HUIRX Therapeutics, Inc.200